€1.47
0.40% today
L&S, Jul 04, 10:15 pm CET
ISIN
US67577R1023
Symbol
OCUP
Sector
Industry

Ocuphire Pharma Inc Stock price

$1.58
-0.10 5.95% 1M
-1.50 48.70% 6M
-1.43 47.51% YTD
-2.70 63.08% 1Y
-3.32 67.76% 3Y
-19.42 92.48% 5Y
-406.90 99.61% 10Y
Nasdaq, Closing price Wed, Jul 03 2024
+0.03 1.94%
ISIN
US67577R1023
Symbol
OCUP
Sector
Industry

Key metrics

Market capitalization $40.96m
Enterprise Value $-6.21m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.95
EV/Sales (TTM) EV/Sales -0.33
P/S ratio (TTM) P/S ratio 2.15
P/B ratio (TTM) P/B ratio 0.86
Revenue growth (TTM) Revenue growth -54.30%
Revenue (TTM) Revenue $19.01m
EBIT (operating result TTM) EBIT $-12.14m
Free Cash Flow (TTM) Free Cash Flow $-3.18m
Cash position $47.17m
EPS (TTM) EPS $-0.49
P/E forward negative
P/S forward 2.51
EV/Sales forward negative
Short interest 4.92%
Show more

Is Ocuphire Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

Ocuphire Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
100%

Financial data from Ocuphire Pharma Inc

Dec '23
+/-
%
Net Profit -9.99 -9.99
156% 156%
-52%
Depreciation and Amortization 0.01 0.01
-
0%
Stock Compensation 3.51 3.51
94% 94%
18%
Operating Cash Flow -1.11 -1.11
108% 108%
-6%
Investments - -
-
-
Dividend Paid - -
-
-
Free Cash Flow -1.11 -1.11
108% 108%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Ocuphire Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocuphire Pharma Inc Stock News

Neutral
GlobeNewsWire
28 days ago
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy (DR) will be featured...
Neutral
GlobeNewsWire
about 2 months ago
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
about 2 months ago
FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial evaluating APX3330 in diabetic retinopathy (DR) on a validated binocular person-level scale...
More Ocuphire Pharma Inc News

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Employees 14
Founded 2018
Website www.ocuphire.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today